Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Long-term weight loss with sibutramine: a randomized controlled trial.

Wirth A, Krause J.

JAMA. 2001 Sep 19;286(11):1331-9.

PMID:
11560538
2.

Long-term effects of weight-reducing drugs in people with hypertension.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.

Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. Review.

PMID:
26934640
3.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
4.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
5.

The efficacy and safety of sibutramine for weight loss: a systematic review.

Arterburn DE, Crane PK, Veenstra DL.

Arch Intern Med. 2004 May 10;164(9):994-1003. Review.

PMID:
15136309
6.

Sibutramine: a novel new agent for obesity treatment.

Ryan DH, Kaiser P, Bray GA.

Obes Res. 1995 Nov;3 Suppl 4:553S-559S. Review.

7.

A benefit-risk assessment of sibutramine in the management of obesity.

Nisoli E, Carruba MO.

Drug Saf. 2003;26(14):1027-48. Review.

PMID:
14583064
8.

Long-term effects of weight-reducing drugs in hypertensive patients.

Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007654. doi: 10.1002/14651858.CD007654.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD007654.

PMID:
19588440
9.

Long-term effects of weight-reducing drugs in hypertensive patients.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD007654.

PMID:
23543553
10.

Sibutramine. A review of its contribution to the management of obesity.

McNeely W, Goa KL.

Drugs. 1998 Dec;56(6):1093-124. Review.

PMID:
9878996
11.

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.

Luque CA, Rey JA.

Ann Pharmacother. 1999 Sep;33(9):968-78. Review.

PMID:
10492502
12.

Pharmacotherapy for obesity.

Ioannides-Demos LL, Proietto J, McNeil JJ.

Drugs. 2005;65(10):1391-418. Review.

PMID:
15977970
13.

Sibutramine lost and found.

Bosello O, Carruba MO, Ferrannini E, Rotella CM.

Eat Weight Disord. 2002 Sep;7(3):161-7. Review.

PMID:
12452247
14.

Treatment of Pediatric Obesity: An Umbrella Systematic Review.

Rajjo T, Mohammed K, Alsawas M, Ahmed AT, Farah W, Asi N, Almasri J, Prokop LJ, Murad MH.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):763-775. doi: 10.1210/jc.2016-2574. Review.

PMID:
28359101
15.

Clinical use of sibutramine.

Ryan DH.

Drugs Today (Barc). 2004 Jan;40(1):41-54. Review.

PMID:
14988769
16.
17.

Association of run-in periods with weight loss in obesity randomized controlled trials.

Affuso O, Kaiser KA, Carson TL, Ingram KH, Schwiers M, Robertson H, Abbas F, Allison DB.

Obes Rev. 2014 Jan;15(1):68-73. doi: 10.1111/obr.12111. Epub 2013 Sep 30. Review.

Supplemental Content

Support Center